New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:19 EDTPTX, GSKClosing of Pernix transaction to acquire Treximet tablets from GSK delayed
Pernix Therapeutics Holdings (PTX) announced that the closing of its transaction to acquire the U.S. rights to Treximet for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The company is working with GlaxoSmithKline (GSK) to ensure sufficient supply to meet anticipated demand. The company and its lenders are also performing additional due diligence related to this supply issue. Doug Drysdale, Chairman, President and CEO of Pernix said, “We are working with our lenders to complete our review and remain optimistic about our ability to close the acquisition of Treximet. We hope to complete our due diligence and the financing necessary in the near future.”
News For PTX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:20 EDTGSKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTPTX, GSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information
April 16, 2015
12:37 EDTPTXOn The Fly: Top stock stories at midday
Subscribe for More Information
09:18 EDTPTXOn The Fly: Pre-market Movers
Subscribe for More Information
09:14 EDTGSKAdamis says albuterol HFA product study met clinical FEV1 primary endpoint
Subscribe for More Information
08:15 EDTGSKGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.
April 15, 2015
18:56 EDTPTXOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTPTXPernix Therapeutics says results impacted by lower Treximet prescription volume
Subscribe for More Information
16:05 EDTPTXPernix Therapeutics sees FY15 revenue$220M-$240M, consensus $237.47M
Subscribe for More Information
16:04 EDTPTXPernix Therapeutics sees Q1 revenue $32M-$35M, consensus $49.52M
Subscribe for More Information
16:02 EDTPTXPernix announces private placement of $120M convertible senior notes due 2021
Subscribe for More Information
11:53 EDTGSKGlaxoSmithKline initiated with a Sell at Societe Generale
April 7, 2015
07:14 EDTGSKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use